Physician profile
Susan List
NPI 1003323429
$6,100.65
in general payments reported to CMS, 2019-2025
19 companies · $3,262 in 2025
The $3,262 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,839 · 2025: $3,262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,096 · Education: $4.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,096.12 |
| Education | $4.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $837.03 | 2024-2025 | Caplyta |
| Alkermes, INC. | $779.95 | 2024-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $691.22 | 2024-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Janssen Pharmaceuticals, INC | $683.67 | 2024-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Neurocrine Biosciences, INC. | $592.40 | 2024-2025 | Ingrezza |
| Abbvie INC. | $554.63 | 2024-2025 | |
| Axsome Therapeutics, INC. | $406.88 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $389.06 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $324.49 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $300.49 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $172.21 | 2024-2025 | Austedo Xr, Austedo Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $121.37 | 2024-2025 | Trintellix |
| Almatica Pharma LLC | $77.79 | 2024 | Loreev Xr |
| Noven Therapeutics, LLC | $59.78 | 2024-2025 | Xelstrym |
| Eisai INC. | $28.46 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $26.29 | 2024 | Azstarys |
| Braeburn INC. | $21.05 | 2024 | Brixadi |
| Boston Scientific Corporation | $20.72 | 2024 | |
| Idorsia Pharmaceuticals US INC | $13.16 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan List listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.